Pharmacotherapy Through the Inhibition of Glycine Transporters: An Update on and Beyond Schizophrenia

Singer, Philipp; Yee, Benjamin K.

doi:10.1007/978-3-319-53126-7_28

Psychiatry and Neuroscience Update - Vol. II 2017

DOI: 10.1007/978-3-319-53126-7_28

|View full text |Cite

Pharmacotherapy Through the Inhibition of Glycine Transporters: An Update on and Beyond Schizophrenia

Philipp Singer

Benjamin K. Yee

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2021

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another problem with inclusion of chronic patients in phase III studies is the fact that there is evidence of glutamate abnormalities which are more pronounced in the early stages of the disease and that drugs targeting this system can only have an effect on patients in the early stages of the disease. These considerations suggest that future studies should focus on patients in the early stages of the disease [3,4].…”

mentioning

confidence: 99%

Glycine transporter inhibitors

Peitl

Vlahović

2020

Arch. Psychiatry Res.

View full text Add to dashboard Cite

Current treatment of schizophrenia offers a wide variety of psychopharmaceuticals that are licensed as first-line treatments for this disorder. However, if we consider their dominant mechanism of action, choice eventually narrows, in some instances considerably. In light of the facts that one third of patients do not respond to standard treatment and that current treatment options do not affect all schizophrenia symptom dimensions, it is not hard to conclude that there is an unsatisfied need which should drive the development of new treatment modalities focusing on other neurotransmitter systems beside dopamine and serotonin [1]. There have been recent discoveries in terms of convergent and convincing evidence from pharmacological, autoimmune, and genetic studies which have confirmed that impaired glutamatergic N-methyl-D-aspartate (NMDA) receptor function can produce psychotic symptoms and that it is involved in the pathogenesis of schizophrenia. Glycine transporters 1 (GlyT1) play a key role in terminating the activity of glycine, which is released into synapses from glial cells to bind

show abstract

mentioning

confidence: 99%

Glycine transporter inhibitors

Peitl

Vlahović

2020

Arch. Psychiatry Res.

View full text Add to dashboard Cite

show abstract

Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder

Goodman

Storch

Sheth

2021

AJP

109

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pharmacotherapy Through the Inhibition of Glycine Transporters: An Update on and Beyond Schizophrenia

Cited by 2 publications

References 95 publications

Glycine transporter inhibitors

Glycine transporter inhibitors

Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder

Contact Info

Product

Resources

About